huCART19-IL18-CD428z Cells for CD19+ Cancers in HIV

This trial tests a new treatment called huCART19-IL18-CD428z cells, a type of cell therapy, for individuals with HIV who have certain cancers, such as Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, Acute Lymphoblastic Leukemia, and Richter’s Transformation. The researchers aim to assess the safety and effectiveness of this treatment for those who have not responded to other treatments. This study may suit individuals with HIV who have these cancers and have found previous treatments unsuccessful. As a Phase 1 trial, the research focuses on understanding how the treatment works in people, offering participants the chance to be among the first to receive this innovative therapy.

The trial does not specify if you need to stop taking your current medications, but you must be stable on your current antiretroviral therapy (ART) without changes for at least 28 days before joining. Your ART regimen cannot include a non-nucleoside reverse transcriptase inhibitor (NNRTI).

Research has shown that huCART19-IL18-CD428z cells are still in early testing stages, so limited information exists about their safety in humans. As a Phase 1 trial, this marks the first time the treatment is tested in people. This phase primarily assesses the treatment's safety and potential side effects.

Unlike standard treatments for CD19+ cancers in HIV, which often involve chemotherapy and monoclonal antibodies, huCART19-IL18-CD428z cells use a unique approach by harnessing the power of genetically modified immune cells. This treatment is derived from CAR-T cell therapy, where a patient's T-cells are modified to target and destroy cancer cells more effectively. The addition of IL-18 and CD428z components potentially enhances the immune response, offering a more robust and sustained attack against cancer cells. Researchers are excited because this innovative mechanism could lead to improved outcomes and fewer side effects compared to traditional therapies.

Research has shown that a new treatment using special cells called huCART19-IL18-CD428z shows promise for treating certain types of cancer. In one study, these cells effectively treated patients with lymphoma who hadn't responded to other treatments. Some patients even experienced a complete response, meaning their cancer was no longer detectable after treatment. Another study found that 82% of patients saw their cancer shrink or disappear. These results suggest this treatment could be a strong option for people with conditions like Non-Hodgkin Lymphoma, Chronic Lymphocytic Leukemia, and similar cancers.⁶⁷⁸⁹¹⁰